Mankind Pharma Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Thu Apr 23 2026

The Mankind Pharma share price target 2026 stands at Rs 2,455-2,805 as per analyst consensus — implying 19-37% upside from the current CMP of Rs 2,055. Investors tracking the Mankind Pharma share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Mankind Pharma (MANKIND) achieves or misses this 12-month target. This article covers every dimension of the Mankind Pharma share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Mankind Pharma on Univest.

Table of Contents

Mankind Pharma Share Price Overview — April 2026

Company	Mankind Pharma
NSE Symbol	MANKIND
Sector	Pharma / Domestic Branded / OTC / Consumer Health
CMP April 2026	Rs 2,055
52-Week High	Rs 2,805
52-Week Low	Rs 1,685
Market Cap	Rs 82,200 Cr
Trailing P/E	38x
Dividend FY26	Rs 3
Promoter Holding	79.8%
FII Holding	8.4%
12M Analyst Target	Rs 2,455-2,805
Upside from CMP	19-37%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Mankind Pharma price, FII/DII flows and analyst targets on the Univest Screener.

What Is Mankind Pharma?

Get Free Analyst Research on Mankind Pharma — Tap Here.

Mankind Pharma (NSE: MANKIND) is one of India’s fastest-growing domestic pharma companies — OTC brands Manforce, Prega News, Gas-O-Fast. 12,000-strong MR force in Tier 2 and 3 cities. FY26 revenue crossed Rs 12,000 crore.

Budget 2026-27 Impact on Pharma

Budget 2026-27’s Ayushman expansion and health insurance penetration growth expand Mankind’s OTC and branded generic addressable market in Tier 2 and 3 cities.

Mankind Pharma share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 2,455	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 2,455-2,805	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 1,685 zone	FY27 miss and extended FII selling

Compare Mankind Pharma with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Mankind Pharma share price target 2026

1. India Pharma Sector — Structural Growth Tailwind

India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Mankind Pharma’s market position within this sector creates compounding runway that underpins the Mankind Pharma share price target 2026 consensus of Rs 2,455-2,805. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Mankind Pharma to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Mankind Pharma share price target 2026 consensus of Rs 2,455-2,805. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Mankind Pharma holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Mankind Pharma share price target 2026 of Rs 2,455-2,805.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Mankind Pharma’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Mankind Pharma share price target 2026 of Rs 2,455-2,805 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Mankind Pharma’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Mankind Pharma share price target 2026 bull case.

Download the Univest iOS App or Android App for live Mankind Pharma alerts and SEBI-registered research.

5 Risks That Could Impact the Mankind Pharma share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Mankind Pharma. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Mankind Pharma share price target 2026 consensus of Rs 2,455-2,805.

2. Valuation at 38x Requires Consistent Execution

At 38x trailing P/E, Mankind Pharma is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Mankind Pharma share price target 2026. The Rs 1,685 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma

Domestic and global competitors are investing aggressively in Mankind Pharma’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Mankind Pharma share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Mankind Pharma share price target 2026 of Rs 2,455-2,805.

5. FII Selling Risk — 8.4% Institutional Holding

With 8.4% FII ownership, Mankind Pharma is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Mankind Pharma share price target 2026 analyst consensus of Rs 2,455-2,805.

Mankind Pharma Bull Case vs Bear Case — Mankind Pharma share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	2,805	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 2,455-2,805	High	FY27 in-line earnings, stable macro
Bear Case	Rs 1,685 zone	Low	FY27 guidance cut, prolonged FII selling

Mankind Pharma Share Price Reference Table

NSE Symbol	MANKIND
CMP	Rs 2,055
52-Week High	Rs 2,805
52-Week Low	Rs 1,685
Market Cap	Rs 82,200 Cr
P/E	38x
Promoter	79.8%
FII	8.4%
Dividend FY26	Rs 3
Short-Term Target	Rs 2,455
12M Target	Rs 2,455-2,805
Upside	19-37%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Mankind Pharma share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 2,466	FY27 earnings recovery and Pharma sector leadership
YES Securities	Buy	Rs 2,507	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 2,363	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Mankind Pharma.

How to Invest in Mankind Pharma — 5 Steps

Step 1: Research on the Univest Screener

Search MANKIND on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Mankind Pharma share price target 2026.

Step 2: Identify Entry Level

Mankind Pharma at Rs 2,055 has key support near Rs 1,685. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Mankind Pharma share price target 2026 recovery is Rs 2,455.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 2,805 — the bull case for the Mankind Pharma share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Mankind Pharma share price target 2026.

Conclusion — Mankind Pharma share price target 2026

Mankind Pharma (MANKIND) at Rs 2,055 offers 19-37% potential upside to the 12-month Mankind Pharma share price target 2026 consensus of Rs 2,455-2,805. The bull case to 2,805 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 1,685 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Mankind Pharma at current levels presents a monitored entry opportunity. For more Mankind Pharma share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Mankind Pharma share price target 2026

Q: What is Mankind Pharma share price target for 2026?

The 12-month Mankind Pharma share price target 2026 analyst consensus is Rs 2,455-2,805 — implying 19-37% upside from CMP Rs 2,055. Bull case: 2,805. Bear case: Rs 1,685 zone. Track the live Mankind Pharma share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Mankind Pharma a good buy at Rs 2,055?

This article does not constitute investment advice. At Rs 2,055, Mankind Pharma offers 19-37% upside to the Mankind Pharma share price target 2026 consensus of Rs 2,455-2,805. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Mankind Pharma 52-week high and low?

Mankind Pharma’s 52-week high is Rs 2,805 and 52-week low is Rs 1,685. At the current CMP of Rs 2,055, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Mankind Pharma share price target 2026 thesis.

Q: What sector is Mankind Pharma (MANKIND) in?

Mankind Pharma operates in the Pharma / Domestic Branded / OTC / Consumer Health sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Mankind Pharma share price target 2026 bull case.

Q: What are the main risks for the Mankind Pharma share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 38x requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (8.4% holding). Monitor quarterly earnings closely.

Q: What is Mankind Pharma’s market cap?

Mankind Pharma has a market cap of Rs 82,200 Cr as of April 2026. At the Mankind Pharma share price target 2026 of Rs 2,455-2,805, the implied market cap would reflect 19-37% appreciation on the current base.

Q: What is Mankind Pharma dividend for FY26?

Mankind Pharma’s FY26 dividend is Rs 3. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Mankind Pharma share price target 2026 capital appreciation potential.

Q: How to buy Mankind Pharma shares?

Buy Mankind Pharma (MANKIND) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 1,685 support zone, and download the Univest App for SEBI-registered research on the Mankind Pharma share price target 2026.